Categories: News

HTX Approved for Pakistan Crypto Exchange Registration

ISLAMABAD, Pakistan, Dec. 12, 2025 /PRNewswire/ — HTX, one of the world’s leading digital asset exchanges with over 50 million registered users globally, today announced that it has officially obtained a No Objection Certificate (NoC) from the Pakistan Virtual Asset Regulation Authority (PVARA) to initiate the licensing process in terms of the Virtual Assets Ordinance, 2025.

- Advertisement -

This landmark NoC makes HTX amongst one of the first global digital asset platforms to begin the formal licensing journey in Pakistan, marking a major milestone in the country’s progression toward a regulated and innovative digital asset ecosystem. Following the issuance of the NoC, HTX will proceed with the necessary steps under the Ordinance to secure full authorization while engaging closely with PVARA throughout the process.

- Advertisement -

By securing this NoC from PVARA, HTX will register with the Financial Monitoring Unit (FMU) for anti-money laundering (AML) -registered services, which include Exchange, Broker dealer, custody and derivatives services, while preparing for full Virtual Asset Service Provider (VASP) licensing.

- Advertisement -

Justin Sun, Global Advisor to HTX, commented:
“Pakistan is one of the fastest-growing crypto markets in the world, with millions of young, tech-savvy users eager to participate in the global digital economy. We are honored to be granted this NoC by PVARA and are committed to working closely with the Authority to set the highest industry standards of compliance, transparency, and user protection. Today’s approval is not just a recognition for HTX—it is a vote of confidence in Pakistan’s vision for crypto adoption.”

- Advertisement -

About HTX

- Advertisement -

Founded in 2013, HTX (formerly Huobi) has evolved from a virtual asset exchange into a comprehensive ecosystem of blockchain businesses that span digital asset trading, financial derivatives, research, investments, incubation, and other businesses.

- Advertisement -

As a world-leading gateway to Web3, HTX harbors global capabilities that enable it to provide users with safe and reliable services. Adhering to the growth strategy of “Global Expansion, Thriving Ecosystem, Wealth Effect, Security & Compliance,” HTX is dedicated to providing quality services and values to virtual asset enthusiasts worldwide.

- Advertisement -

To learn more about HTX, please visit https://www.htx.com/ or HTX Square , and follow HTX on X, Telegram, and Discord.

- Advertisement -

Logo – https://mma.prnewswire.com/media/2391903/image_ID__Logo.jpg

- Advertisement -

View original content:https://www.prnewswire.co.uk/news-releases/htx-approved-for-pakistan-crypto-exchange-registration-302640282.html

- Advertisement -

Recent Posts

Crypto News: AlphaPepe Presale Records Surge in Whale Accumulation As Bitcoin Price Prediction Eyes $180,000

MONACO, May 16, 2026 (GLOBE NEWSWIRE) -- Crypto news is turning toward AlphaPepe after the…

5 hours ago

Crypto Market News: AlphaPepe Finalizes Tier-1 Exchange Shortlist as XRP Price Prediction Targets $5.00

MONACO, May 16, 2026 (GLOBE NEWSWIRE) -- Crypto market news is turning toward AlphaPepe after…

5 hours ago

Qoder Version 1.0 Released: Full Automation of Code Generation, Verification & Delivery

SINGAPORE, May 16, 2026 (GLOBE NEWSWIRE) -- Qoder officially releases version 1.0, upgrading from an…

5 hours ago

Ipsen presents first-in-class late-breaking Phase II corabotase data in glabellar lines showing sustained duration of effect reinforced by consistently high patient satisfaction

Patients treated with corabotase showed a rapid onset of action of 0.84 days and peak effect statistically superior to placeboAt Week 24, 60.8% of patients treated with corabotase experienced clinically…

5 hours ago

ImPact Biotech Presents Updated Data from Phase 3 ENLIGHTED Trial of Padeliporfin VTP in LG-UTUC at AUA 2026

– Complete response (CR) observed in 70% (50/72) of evaluable patients with low-grade upper tract…

5 hours ago

Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers

- Stenoparib clinical development continues in relapsed small cell lung cancer and, under FDA Fast…

5 hours ago